drugset
drugset / Trial / NCT07077798

Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection

NCT07077798 ↗

Not yet recruiting 234 enrolled Wan-Guang Zhang
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Vessels that encapsulate tumor clusters (VETC) are a novel invasive metastatic factor in hepatocellular carcinoma (HCC), operating independently of the epithelial-mesenchyme transition (EMT). The presence of VETC is associated with a higher rate of postoperative recurrence in HCC patients, indicating a more aggressive biological behavior.Improving the prognosis for VETC-positive patients is a critical issue in clinical oncology.

Timeline

Start
2025-08-01
Primary completion
2026-08-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenvatinib Small molecule 8 mg Oral
Subject Lenvatinib Small molecule 12 mg Oral
Subject Sintilimab Monoclonal antibody 200 mg Intravenous

Indications

hepatocellular carcinoma